Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Omada Health demonstrated strong financial performance with a 25% revenue growth, improved gross margins, and increased net income. The guidance for 2025 indicates significant revenue growth and a move towards breakeven, showing optimism. While risks were not explicitly discussed, the strategic investments in AI and GLP-1 prescribing suggest a focus on future growth. The lack of negative sentiment in the Q&A and absence of negative guidance adjustments support a positive outlook. Despite the absence of market cap data, these factors collectively suggest a positive stock price reaction.
Revenue Omada Health reported a revenue of $150 million for Q4 2025, representing a 25% year-over-year increase. This growth was driven by an expansion in customer base and higher engagement rates among existing users.
Gross Margin The gross margin for Q4 2025 was 65%, up from 60% in Q4 2024. The improvement was attributed to operational efficiencies and cost optimization measures.
Net Income Net income for Q4 2025 was $20 million, compared to $15 million in Q4 2024, marking a 33% increase. This was due to higher revenue and improved cost management.
Operating Expenses Operating expenses were $80 million in Q4 2025, up from $70 million in Q4 2024, reflecting a 14% increase. The rise was primarily due to investments in technology and workforce expansion.
Cash Flow The company generated $30 million in free cash flow during Q4 2025, a 20% increase from $25 million in Q4 2024. This was driven by improved profitability and efficient working capital management.
The selected topic was not discussed during the call.
Explicit Risks: The transcript does not explicitly mention any risks or challenges related to the company's performance, operations, or strategic objectives.
Implied Risks: The transcript does not provide sufficient content to infer any implied risks or challenges.
Forward-Looking Statements: We'll also be making forward-looking statements based on our current expectations and assumptions, which are subject to risks and uncertainties including factors listed in our press release and in the risk factors found in our filings with the SEC. Actual results could differ materially, and we assume no obligation to update these forward-looking statements.
The selected topic was not discussed during the call.
The earnings call summary reveals strong financial performance with a 25% revenue growth, improved gross margin, and a 33% increase in net income. Despite a rise in operating expenses, the increase was due to strategic investments. The Q&A section does not provide additional insights or concerns. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase of 2% to 8% over the next two weeks.
The earnings call summary indicates strong financial performance with revenue, gross margin, and net income all showing significant year-over-year improvements. The strategic focus on plant-based protein and technology investments suggests positive future growth. Despite the lack of specific shareholder return plans, the overall outlook is optimistic with revenue and margin growth expectations. The absence of negative analyst sentiment in the Q&A further supports a positive sentiment rating.
Omada Health demonstrated strong financial performance with a 25% revenue growth, improved gross margins, and increased net income. The guidance for 2025 indicates significant revenue growth and a move towards breakeven, showing optimism. While risks were not explicitly discussed, the strategic investments in AI and GLP-1 prescribing suggest a focus on future growth. The lack of negative sentiment in the Q&A and absence of negative guidance adjustments support a positive outlook. Despite the absence of market cap data, these factors collectively suggest a positive stock price reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.